Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2011

01-04-2011 | Thoracic Oncology

Disease-Related Mortality within the First Year after Subtotal Esophagectomy for Cancer

Authors: Guy Pines, MD, Yoram Klein, MD, Victor Buyeviz, MD, Efraim Idelevich, MD, Hanoch Kashtan, MD

Published in: Annals of Surgical Oncology | Issue 4/2011

Login to get access

Abstract

Background

Esophageal carcinoma has poor prognosis. Surgery is still considered to be the mainstay of treatment. The mortality rate within the first year after surgery is unknown, but identifying risk factors for early mortality would increase our ability to predict the outcome of these patients and might improve patient selection.

Methods

All patients who had undergone subtotal esophagectomy for cancer between 2003 and 2008 were included in this retrospective series. Patients with less than 12 months follow-up, perioperative mortality, and death from unrelated causes were excluded. Patients were divided into two groups. Group A included all oncological mortality cases within 12 months of surgery. Group B included all patients who survived longer than 12 months following surgery.

Results

Of 81 patients who met the inclusion criteria, group A included 18 patients and group B included 63 (median survival 10 and 25 months, respectively). A higher proportion of patients were operated for pN1 disease in group A (72% versus 33%, p = 0.0004). R0 esophagectomy rate was lower in group A (39% versus 76%, p = 0.03). Metastatic lymph node ratio (LNR) was higher in group A (mean: 46% versus 10%, p = 0.0003). Multivariate analysis identified LNR as an independent risk factor for first-year oncological mortality [odds ratio (OR) = 1.04, p = 0.0001; 95% confidence interval (CI): 1.02–1.06]. No differences were found in preoperative variables including age, gender, tumor histology, type of operation, and administration of or response to neoadjuvant therapy. Response to neoadjuvant therapy was associated with R0 resection.

Conclusions

pN1 disease, resection margin involvement, and high LNR were found to be risk factors for first-year oncological mortality after esophagectomy for cancer.
Literature
1.
2.
go back to reference Sabanathan S, et al. Results of surgical treatment of oesophageal cancer. J R Coll Surg Edinb. 1996;41(5):295–301.PubMed Sabanathan S, et al. Results of surgical treatment of oesophageal cancer. J R Coll Surg Edinb. 1996;41(5):295–301.PubMed
3.
go back to reference Morstyn G, et al. Improved survival in esophageal cancer in the period 1978 to 1983. J Clin Oncol. 1986;4(7):1062–7.PubMed Morstyn G, et al. Improved survival in esophageal cancer in the period 1978 to 1983. J Clin Oncol. 1986;4(7):1062–7.PubMed
4.
go back to reference Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):481–8.PubMedCrossRef Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):481–8.PubMedCrossRef
5.
go back to reference Pines G, et al. The use of circular stapler for cervical esophagogastric anastomosis after esophagectomy: surgical technique and early postoperative outcome. Dis Esophagus. 2009;22(3):274–8.PubMedCrossRef Pines G, et al. The use of circular stapler for cervical esophagogastric anastomosis after esophagectomy: surgical technique and early postoperative outcome. Dis Esophagus. 2009;22(3):274–8.PubMedCrossRef
6.
go back to reference Bedenne L, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRef Bedenne L, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRef
7.
go back to reference Coia LR, et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1991;20(1):29–36.PubMedCrossRef Coia LR, et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1991;20(1):29–36.PubMedCrossRef
8.
go back to reference Leichman L, et al. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol. 1987;5(3):365–70.PubMed Leichman L, et al. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol. 1987;5(3):365–70.PubMed
9.
go back to reference Seitz JF, et al. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer. 1990;66(2):214–9.PubMedCrossRef Seitz JF, et al. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer. 1990;66(2):214–9.PubMedCrossRef
10.
go back to reference Sobon LH, Wittekind, C, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002. Sobon LH, Wittekind, C, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002.
11.
go back to reference Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef
12.
go back to reference Idelevich E, et al. Overall survival with cisplatin and 5-fluorouracil neoadjuvant treatment in patients with esophageal cancer: single-center experience. Onkologie. 2008;31(12):673–7.PubMedCrossRef Idelevich E, et al. Overall survival with cisplatin and 5-fluorouracil neoadjuvant treatment in patients with esophageal cancer: single-center experience. Onkologie. 2008;31(12):673–7.PubMedCrossRef
13.
go back to reference Allum WH, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRef Allum WH, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRef
14.
go back to reference Stahl M, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef Stahl M, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef
15.
go back to reference Wijnhoven BP, et al. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 2007;245(5):717–25.PubMedCrossRef Wijnhoven BP, et al. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 2007;245(5):717–25.PubMedCrossRef
16.
go back to reference Thompson SK, et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol. 2008;15(12):3447–58.PubMedCrossRef Thompson SK, et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol. 2008;15(12):3447–58.PubMedCrossRef
17.
go back to reference Rice TW, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116(16):3763–73.PubMedCrossRef Rice TW, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116(16):3763–73.PubMedCrossRef
18.
go back to reference Peyre CG, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248(6):979–85.PubMedCrossRef Peyre CG, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248(6):979–85.PubMedCrossRef
19.
go back to reference Nitti D, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol. 2003;10(9):1077–85.PubMedCrossRef Nitti D, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol. 2003;10(9):1077–85.PubMedCrossRef
20.
go back to reference Peng J, et al. Prognostic significance of the metastatic lymph node ratio in node-positive rectal cancer. Ann Surg Oncol. 2008;15(11):3118–23.PubMedCrossRef Peng J, et al. Prognostic significance of the metastatic lymph node ratio in node-positive rectal cancer. Ann Surg Oncol. 2008;15(11):3118–23.PubMedCrossRef
21.
go back to reference Bando E, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol. 2002;9(8):775–84.PubMedCrossRef Bando E, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol. 2002;9(8):775–84.PubMedCrossRef
22.
go back to reference Nigro JJ, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg. 1999;117(5):960–8.PubMedCrossRef Nigro JJ, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg. 1999;117(5):960–8.PubMedCrossRef
23.
24.
go back to reference Mariette C, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247(2):365–71.PubMedCrossRef Mariette C, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247(2):365–71.PubMedCrossRef
25.
go back to reference Dexter SP, et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001;48(5):667–70.PubMedCrossRef Dexter SP, et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001;48(5):667–70.PubMedCrossRef
26.
go back to reference Scheepers JJ, et al. Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route. Dis Esophagus. 2009;22(1):42–8.PubMedCrossRef Scheepers JJ, et al. Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route. Dis Esophagus. 2009;22(1):42–8.PubMedCrossRef
27.
go back to reference Barbour AP, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.PubMedCrossRef Barbour AP, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.PubMedCrossRef
28.
go back to reference Griffiths EA, et al. The prognostic value of circumferential resection margin involvement in oesophageal malignancy. Eur J Surg Oncol. 2006;32(4):413–9.PubMedCrossRef Griffiths EA, et al. The prognostic value of circumferential resection margin involvement in oesophageal malignancy. Eur J Surg Oncol. 2006;32(4):413–9.PubMedCrossRef
29.
go back to reference Machlenkin S, Melzer E, Idelevich E, Ziv-Sokolovsky N, Klein Y, Kashtan H. Endoscopic ultrasound: doubtful accuracy for restaging of esophageal cancer after preoperative chemotherapy. Isr Med Assoc J. 2009;11(3):166–9.PubMed Machlenkin S, Melzer E, Idelevich E, Ziv-Sokolovsky N, Klein Y, Kashtan H. Endoscopic ultrasound: doubtful accuracy for restaging of esophageal cancer after preoperative chemotherapy. Isr Med Assoc J. 2009;11(3):166–9.PubMed
30.
go back to reference Krasna MJ, et al. Combined thoracoscopic/laparoscopic staging of esophageal cancer. J Thorac Cardiovasc Surg. 1996;111(4):800–6; discussion 806–7.PubMedCrossRef Krasna MJ, et al. Combined thoracoscopic/laparoscopic staging of esophageal cancer. J Thorac Cardiovasc Surg. 1996;111(4):800–6; discussion 806–7.PubMedCrossRef
31.
go back to reference Krasna MJ, et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg. 2001;71(4):1073–9.PubMedCrossRef Krasna MJ, et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg. 2001;71(4):1073–9.PubMedCrossRef
32.
go back to reference Krasna MJ, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech. 2002;12(4):213–8.PubMedCrossRef Krasna MJ, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech. 2002;12(4):213–8.PubMedCrossRef
Metadata
Title
Disease-Related Mortality within the First Year after Subtotal Esophagectomy for Cancer
Authors
Guy Pines, MD
Yoram Klein, MD
Victor Buyeviz, MD
Efraim Idelevich, MD
Hanoch Kashtan, MD
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1386-4

Other articles of this Issue 4/2011

Annals of Surgical Oncology 4/2011 Go to the issue